Study analyses benefits and potential harms associated with very low LDL cholesterol.
These clinicians argue against it for patients with low CVD risk.
Cochrane review finds that effects in Black people may be even steeper.
Very low and very high concentrations are both tied to increased risk.
They also develop HF more frequently.
I benefici cardiovascolari sono osservabilii anche in chi ha più di 75 anni, come dimostra una metanalisi condotta su oltre 21.000 anziani.
But the number needed to treat to prevent an event within 5 years is between 42 and 145.
Non esiste un livello definito di C-LDL al di sotto del quale cessi la riduzione del rischio o venga compromessa la sicurezza.
Solo un terzo dei pazienti in Europa sta raggiungendo gli obiettivi lipidici basati sul rischio, dato che riflette l’utilizzo insufficiente delle terapie combinate.
Either modestly improves risk discrimination.
A small randomized crossover study also finds improved cholesterol values.
LDL dropped by 49 percentage points relative to placebo increase.
Pubblicati i risultati del primo studio di fase 3 sull’effetto ipocolesterolemizzante di questo anticorpo monoclonale
Patients with MetS have increased risk for CV mortality, even on statins.
The validity of using LDL cholesterol as a surrogate target for the prevention of cardiovascular disease.
For some, the question is not whether to start but when.
Meta-analysis results suggest benefit of screening, preventive management in prediabetes.
